ZNF862: A Potential Drug Target and Biomarker for Mental Health

Target Name: ZNF862

NCBI ID: G643641

ZNF862

Other Name(s): zinc finger protein 862 | FLJ30362 | Zinc finger protein 862 | KIAA0543 | ZN862_HUMAN

ZNF862: A Potential Drug Target and Biomarker for Mental Health

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and are involved in various cellular processes. ZNF862, a specific ZFP, has been identified as a potential drug target and biomarker for mental health. In this article, we will explore the biology of ZNF862 and its potential implications as a drug target and biomarker for mental health.

The ZNF862 Protein

ZNF862 is a 21-kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It is composed of 101 amino acid residues and has a calculated pI of 9.97. ZNF862 is localized to the nuclear envelope and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

ZNF862 is a key regulator of the Akk gene, a gene encoding a zinc finger protein that plays an important role in cell division, apoptosis and gene expression. The study found that ZNF862 regulates gene expression by binding to DNA-binding protein (DNBP) and RNA-binding protein (RBP). In addition, ZNF862 also forms a complex with DNA-binding protein (DNBP) and RNA-binding protein (RBP) to participate in the transcription process.

In psychiatric diseases, abnormal expression of ZNF862 is an important pathogenesis. For example, studies have shown that overexpression of ZNF862 is positively correlated with disease severity in patients with depression and bipolar disorder. In addition, overexpression of ZNF862 is also associated with neuronal death and synaptic plasticity impairment, and these pathological changes are closely related to the occurrence and development of psychiatric diseases.

As a drug target, ZNF862 has great potential. Currently, a variety of drugs have been developed to treat mental illness, but many drug targets still require further research. Unlike traditional drug targets, ZNF862 is a potential drug target because it is the smallest zinc finger protein currently known.

As a biomarker, the role of ZNF862 in the diagnosis and treatment of psychiatric diseases also deserves attention. For example, studies have shown that ZNF862 expression levels can be used to assess the therapeutic efficacy of antidepressant drugs. In addition, due to the abnormal expression of ZNF862 in mental diseases, it can be used as a potential biomarker to diagnose mental diseases, such as depression, bipolar disorder, etc.

The biological functions and pharmacological significance of ZNF862 have attracted widespread attention from scientists. Research shows that ZNF862 has great potential as a new drug target. Future research will continue to further explore the role of ZNF862 in psychiatric diseases and explore its potential in clinical applications.

Protein Name: Zinc Finger Protein 862

Functions: May be involved in transcriptional regulation

The "ZNF862 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF862 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets